Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
PharmiWeb
7h
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...
GlobalData on MSN
8h
Lilly’s EBGLYSS shows improvement in Phase IIIb study for atopic dermatitis
The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Interagency operation at jail
Jay Johnston sentenced
Plans major layoffs
Rare dime fetches $500K+
‘The Warriors' actor dies
Murder suspect manhunt
Ballot boxes set on fire
Iran warns Israel
Philadelphia DA sues Musk
CA crab season delayed
Nobel laureate hospitalized
Quarter Pounders return
Screenwriter Taylor dies
Rare NYC rally appearance
Oil prices fall
Indonesia bans iPhone 16
Massachusetts brush fire
Egypt proposes Gaza truce
Heat honor Dwyane Wade
Synagogue attack memorial
Stephen Curry injured
N. Korean troops in Ukraine
Announces stock offering
Launches election trading
CA electric motorcycle plan
Reddick wins NASCAR race
On Ukraine's use of US arms
VA appeals voter purge
D-Day veteran dies at 99
Chalamet surprises fans
Norway buys US missiles
Related topics
Eli Lilly and Company
EBGLYSS
Hives
Feedback